For patients who already have flow cytometry, can you just run the drug sensitivity profile?

Yes, our AI-driven Drug Response Predictions Only (DRP) service is available starting May 2024. This service focuses solely on the drug prediction aspect, providing you with insights without the flow cytometry and PARR results.

Other Questions

Back to Help Center

What is the simulated dosing for a certain drug? MTD(maximum tolerated dosing) or metronomic?

Our models don't differentiate between different types of dosing, so they can be viewed as outcomes for standard clinical practice. For instance, if MTD is more common in practice, the models may more closely reflect MTD.

Do you test "rescue" drugs as well?

Yes, many of the 13 anticancer drugs we provide predictions for are used for rescue therapy. The drugs we test against are: L-Asparaginase, Mitoxantrone, Vincristine, Vinblastine, Doxorubicin, Tanovea, Chlorambucil, Mechlorethamine, Lomustine, Prednisone, Cyclophosphamide, Melphalan, and Dexamethasone.

I have a patient with likely lymphoma/leukemia. For a blood sample, can I just submit an EDTA blood tube or do I still use the ImpriMed tubes (and if so, how many tubes and is an additional EDTA blood tube still needed with that)?

If the patient is suspected of leukemia, blood collected in the EDTA tube should be fine. If it is lymphoma, we might need FNA from the affected organ/lymph node. We can suggest FNA in ImpriMed media tube (1) and 2ml of blood sample in an EDTA tube.

Does pet insurance cover ImpriMed?

Most pet insurance plans that cover cancer care will typically cover ImpriMed’s services. Please check with your insurance representative to see if your plan can cover the services.

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.